Biotest AG — Regulatory Filings 2007

Jul 16, 2007

News Details

Corporate | 16 July 2007 07:45

Biotest AG: New clinical results increase market potential of Cytotect®

Biotest AG / Miscellaneous

Release of a Corporate News, transmitted by DGAP – a company of EquityStory

AG.

The issuer / publisher is solely responsible for the content of this announcement.

———————————————————————-

New clinical results increase market potential of Cytotect®

· Scientific study: administration of CMV- immunoglobulins reduces risk of

tumour diseases following transplants

· Data of more than 40,000 patients analysed

· Transplant doctors discuss practice consequences

Dreieich, 16 July 2007. The indication range of Biotest’s immunoglobulin,

Cytotect®, may be expanded. An article published in the renowned medical

magazine ‘Lancet Oncology’ by Prof. Dr. Gerhard Opelz from the Institute

for Immunology at the University of Heidelberg and his colleagues concludes

that the administration of Cytotect® significantly reduces the risk of

lymphomas following organ transplant surgery. The results are based on the

analysis of the data of more than 40,000 patients. The study was

acknowledged in a commentary in the same issue of the magazine, which

emphasises its significance in scientific terms.

Lymphomas (lymph node cancer) present a formidable complication following

transplants, which occurs in 2% to 5% of all patients. The most common

cause of these tumors is infection by the Epstein-Barr virus (EBV). Since

transplant patients’ immune system is inhibited in order to avoid rejection

of the transplanted organ, these patients are at particular risk of

infection by EBV. Cytotect® is already successfully administered as a

prophylaxis against cytomegalovirus infections (CMV) which occur following

transplants. Compared to other immunoglobulins, it contains an especially

high concentration of antibodies against the Epstein-Barr virus.

On 13 July renown experts in the field of transplantation discussed

together with Biotest possible consequences for clinical practice. The

participants were in unanimous agreement that the established CMV

prophylaxis also has a preventive effect on the formation of EBV-induced

lymphomas.

Biotest expects that the new results increase the market potential of

Cytotect®.

About Biotest

Biotest AG, Dreieich, Germany, is a company that researches and

manufactures pharmaceutical, biotherapeutic and diagnostic products and has

specialised in immunology and haematology. In its Pharmaceutical segment,

Biotest develops immunoglobulins, clotting factors and albumins based on

human blood plasma. These are used for diseases of the immune system or

haematopoietic system. In the Biotherapeutic segment, Biotest researches

into the clinical development of monoclonal antibodies, including in the

indications of rheumatoid arthritis and blood cancer. The Diagnostic

segment spans reagents and serology and microbiology systems which are

used, for example, in blood transfusions. Biotest has around 1,200

employees worldwide and its shares are listed in the Frankfurt Stock

Exchange’s Prime Standard.

Biotest AG:

Biotest AG, Landsteinerstr. 5, D-63303 Dreieich, www.biotest.de

Dr. Marion Wendorff, Tel: +49 (0) 6103 801-520, e-mail:

marion_wendorff@biotest.de

Fax: +49 (0) 6103 801-7840

WKN, ISIN ordinary share: 522720, DE0005227201

WKN, ISIN preference share: 522723, DE0005227235

Listed: Prime Standard/official trading

Frankfurt, Berlin, Düsseldorf, Hamburg, Stuttgart

DGAP 16.07.2007

———————————————————————-

Language: English

Issuer: Biotest AG

          Landsteinerstr. 5

          63303 Dreieich Deutschland

Phone: +49 – 6103 / 801 – 0

Fax: +49 – 6103 / 801 – 150

E-mail: mail@biotest.de

Internet: www.biotest.de

ISIN: DE0005227201, DE0005227235

WKN: 522720, 522723

Indices:

Listed: Amtlicher Markt in Frankfurt (Prime Standard); Freiverkehr in

          Berlin, Düsseldorf, Hamburg, Stuttgart

End of News DGAP News-Service

—————————————————————————